Source - RNS
RNS Number : 5677X
Integumen PLC
30 April 2019




30 April 2019


Integumen PLC


("Integumen" or "Company")


Result of General Meeting


At a general meeting held earlier today, all the Resolutions were passed and the Proposals (as set out in the announcement of 12 April 2019) have completed. It is expected that the 476,722,882 New Ordinary Shares, the subject of the Proposals, will be allotted later today, and Admission is expected to take place on Thursday 2 May 2019.




Integumen plc

Gerard Brandon, CEO

+44 (0) 7340 055 643

SPARK Advisory Partners Limited

(Nominated Adviser)

Neil Baldwin/Vassil Kirtchev

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited


Andy Thacker

+44 (0) 20 3621 4120



About Integumen


Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.


The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.

Definitions used in this announcement are the same as those in the announcement of 12 April 2019.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit